Approximately 80% of patients diagnosed with acute myeloid leukemia (AML) die as a consequence of failure to eradicate the tumor from the bone marrow microenvironment. We have recently shown that stroma-derived interleukin-8 (IL-8) promotes AML growth and survival in the bone marrow in response to AML-derived macrophage migration inhibitory factor (MIF). In the present study we show that high constitutive expression of MIF in AML blasts in the bone marrow is hypoxia-driven and, through knockdown of MIF, HIF1α and HIF2α, establish that hypoxia supports AML tumor proliferation through HIF1α signaling. In vivo targeting of leukemic cell HIF1α inhibits AML proliferation in the tumor microenvironment through transcriptional regulation of MIF, but inhibition of HIF2α had no measurable effect on AML blast survival. Functionally, targeted inhibition of MIF in vivo improves survival in models of AML. Here we present a mechanism linking HIF1α to a pro-tumoral chemokine factor signaling pathway and in doing so, we establish a potential strategy to target AML.
Introduction
Survival of patients with acute myeloid leukemia (AML) is poor; two-third of young adults and 90% of older adults die of their disease [1] . Even in patients fit enough to be treated with intensive cytotoxic chemotherapies, despite high initial response rates, relapse is common and occurs from minimal residual disease harbored within the bone marrow microenvironment [2] . Improved outcomes require novel treatment strategies derived from a better understanding of the biology of the tumor and its microenvironment.
Hypoxia is a key microenvironmental factor that influences the biology of the hematopoietic stem cell (HSC), as well as leukemic cells within the bone marrow [3] [4] [5] [6] . The bone marrow microenvironment is hypoxic, and targeting hypoxia inducible genes can eliminate cancer stem cells in hematological malignancies [7] . The hypoxic state is principally maintained by members of the hypoxia-inducible factor (HIF) family. Both HIF1α and HIF2α respond to hypoxia; HIF1α responds to acute hypoxia and HIF2α to a chronic hypoxic state [8] . Despite an increase in the understanding of the different pathways regulated by HIF1α and HIF2α, their role in HSC maintenance and leukemogenesis remains to be delineated [9, 10] . Constitutive HIF1-α expression has been detected in normal karyotype AML and was found to be associated with poor prognosis [11] , moreover, targeting HIF1α in AML cancer stem cells abrogated their colony-forming activity. Recent data showed that HIF2α silencing impairs long-term engraftment of HSC and also inhibits proliferation of primary AML in vitro [12] . Others have shown that HIF2α is high in subsets of both human AML and mouse models of AML, and overexpression of HIF2α accelerated disease progression, however this study also highlights that patients with high HIF2α expression trend toward disease-free survival [13] . Together these data describe a complex interplay between hypoxia-regulated transcription factors HIF1α and HIF2α and there regulatory role in normal HSC and AML.
We have previously shown that AML cells constitutively express high levels of macrophage migration inhibitory factor (MIF), which drives Interleukin-8 (IL-8) expression by the bone marrow mesenchymal stromal cells (BM-MSC), and that in turn supports AML cell survival and proliferation [14] . Furthermore, hypoxia has been identified as a potent inducer of the pro-inflammatory cytokine MIF in inflammatory diseases [15, 16] . Specifically, a singlenucleotide polymorphism mapping to a functional hypoxia response element (HRE) in the MIF locus, prevents induction of MIF by hypoxia [17] . Together, these studies lead us to hypothesize a role for hypoxia in regulating MIF survival signals in AML.
The aim of the present study is to determine if there is a connection between the hypoxic bone marrow microenvironment and MIF in regulating AML survival. If so, to further determine the role of HIF1α and HIF2α in this response, and to evaluate the functional consequences and potential therapeutic effect of inhibiting such a pathway in vivo in AML patient-derived xenograft (PDX) models.
Results
AML blasts derived from the bone marrow express higher levels of MIF compared to blasts in the systemic circulation and spleen
We have previously shown that primary AML cells from the bone marrow constitutively express high levels of MIF, which subsequently drives survival signals within the BM microenvironment [14] . To determine if this is a function of the BM environment, we looked at the expression levels of MIF in AML BM samples compared to AML peripheral blood (PB) samples (GEO accession number GSE49642) [18] . These data show that MIF gene expression was significantly higher in AML samples from the BM compared to those from PB (Fig. 1a) . We next carried out qRT-PCR of five patient-matched primary AML samples (both BM and PB) to show in both samples that AML cells from the BM expressed higher levels of MIF than those taken from the PB (Fig. 1b) . We then used a PDX model, in which nine primary AML patient samples were injected into NSG mice, in order to compare MIF gene expression between AML blasts that engrafted in the BM to blasts engrafted in the spleen (Fig. 1c) . Figure 1d confirms that the primary AML reliably engrafted the BM and spleen of the NSG mice. Figure 1e shows that MIF had a lower deltaCT or dCT (the lower the dCT value the higher the gene expression level) value in the AML blasts from the BM compared to blasts from the spleen.
Hypoxia induces MIF in primary AML blasts
As the BM has been shown to be hypoxic [19] [20] [21] [22] and hypoxia has been shown to regulate the expression of MIF in various cells [16, 17] , we hypothesized that hypoxia was responsible for the higher expression of MIF in AML cells located in the BM. In 2014, Wierenga and colleagues were able to identify common hypoxia-HIF1α-HIF2α gene signatures through the overexpression of HIF1α and HIF2α in CD34+ cord blood cells [23] ; we used the generated HIF1α, HIF2α and hypoxia-specific gene lists to determine the gene signature in the data set used in Fig. 1a . Figure 2a and supplementary data 1 show that a set of hypoxia-related genes are preferentially expressed in AML BM compared to PB, with MIF being a significant gene in this list. To determine whether hypoxic conditions could induce expression of MIF in AML blasts in vitro, we established hypoxic culture conditions either by using the hypoxiamimetic agents cobalt chloride (CoCl 2 ) and desferrioxamine (DFO) (which induce molecular hypoxic responses with similar kinetics to hypoxia) or by using a hypoxic chamber (1% O 2 ). Figure 2b shows the induction of HIF1a protein in AML cells by hypoxia or hypoxia mimic reagents CoCl 2 and DFO. MIF mRNA and protein secretion were then assayed in experiments on five primary BM-derived AML patient samples. Figure 2c and d shows that CoCl 2 , DFO and 1% O 2 all significantly induced MIF mRNA expression and cytokine secretion. Next we sought to determine the contribution of HIF1α or HIF2α in regulating the expression of MIF in BM. We determined the significantly upregulated/enriched hypoxia, HIF1α, and HIF2α genes in AML BM samples compared to AML PB samples (GEO accession number GSE49642). The analysis showed that MIF expression is part of the HIF1α signature but not HIF2α; the VENN diagram (Fig. 2e) shows the distribution and overlap of the differentially expressed genes identified, there are 57 genes including MIF that are regulated by Hypoxia and HIF1α but not HIF2α, based on these findings we hypothesize that HIF1α plays a significant role in upregulating MIF in primary AML. Figure 2f shows that MIF mRNA expression and protein secretion was not induced in nonmalignant CD34+ cells under hypoxia. Together, these results demonstrate that hypoxic regulation of MIF is a tumor-specific event.
HIF1α but not HIF2α is stabilized and induces MIF in primary AML blasts in response to hypoxia
To further characterize the role of HIF1α and HIF2α in primary AML blasts, we assayed for HIF1α and HIF2α protein expression in AML blasts cultured under normoxic and hypoxic conditions. Figure 3a confirms that HIF1α is stabilized under hypoxic conditions in primary AML blasts, however, we found that HIF2α was detected in under normoxic conditions in U937, OCI-AML3 and 5/6 primary AML tested (Fig. 3a, b) . Moreover, only U937 and 1/6 primary AML samples showed an increase in HIF2a under hypoxic conditions. To further characterize the role of HIF1α in regulating MIF and confirm the specificity of the response to HIF1α and not HIF2α, we used lentiviralmediated knockdown (KD) of HIF1α or HIF2α in AML patient blasts. Figure 3c confirms reduced mRNA expression of HIF1α and HIF2α after infection with HIF1α-KD and HIF2α-KD lentivirus. Figure 3d shows that HIF1α or HIF2α stabilization is reduced in AML blasts under hypoxic conditions in KD cells when compared to control-KD (ShE-KD) cells. Figure 3e and f shows that under hypoxic conditions, HIF1α-KD, but not HIF2α-KD, reduced basal levels of secreted MIF in five primary AML patient cells, and reduced leukemic survival by 65% compared to control cells. However, since the KD between HIF1α-KD and HIF2α-KD are not comparable we cannot rule out HIF2α involvement in the up-regulation of MIF. Figure 3g shows that when we treated HIF1α-KD AML cells with MIF, this prevented cell death. Together these results demonstrate that HIF1α regulates MIF secretion in AML blasts under hypoxic conditions. 6 primary AML cells (nine patients with AML) were injected into NSG mice. d Engraftment was measured using human CD33 and human CD45; in the dot plot each AML engraftment into NSG mice is shown for bone marrow and spleen. e RNA was extracted from AML from the BM and spleen. RNA was analyzed for MIF mRNA using humanspecific primers. mRNA differences are presented as delta cycle threshold (dCT), normalized to human β-actin
HIF1α regulated MIF functions to promote AML tumor proliferation in vitro
To understand the importance of HIF1α-regulated MIF for the survival of AML cells within the bone marrow microenvironment, we used a lentiviral-mediated KD of MIF in our in vitro and in vivo AML assays. Reduced mRNA and protein expression of MIF after lentiviral targeting was confirmed prior to functional analysis (Fig. 4a,  b) . MIF-KD in AML significantly reduced IL-8 mRNA Fig. 2 Hypoxia induces MIF expression in Primary AML blasts. a Heatmap of genes that are differentially expressed between bone marrow and peripheral blood AML samples (adjusted p < 0.05, significance analysis of microarrays) (data from GSE49642). Only genes that are upregulated under hypoxia are displayed [23] . Samples (columns) are grouped according to the type of sample: bone marrow (black) or peripheral blood (gray). The expression of individual genes (rows) across the data set is represented by mean-centered log 2 expression values. The genes are ordered from top to bottom by descending fold change. b AML cells were treated with CoCl 2 (100 µM), DFO (150 µM) or cultured under hypoxic conditions (1% O 2 ) for 4 h, then protein was extracted and Western blotting was performed. c Primary AML cells were treated with CoCl 2 (100 µM) or DFO (150 µM) for 4 h and cultured under hypoxic conditions for 24 h, RNA was extracted and MIF mRNA expression was determined with RT-PCR. Data represented as mean ± standard deviation (n = 5) (p < 0.05). d Media was collected from the respective conditions described in b and MIF protein secretion was determined by target-specific ELISA, Data represented as mean ± standard deviation (n = 5) (p < 0.05). e Venn diagram showing overlaps in genes up regulated upon induction of hypoxia, overexpression of HIF1α and HIF2α. f Non-malignant CD34 + cells were cultured under hypoxic conditions for 24 h. Culture media was assayed for MIF cytokine secretion and RNA was extracted and MIF mRNA expression was determined with RT-PCR. Data represented as mean ± standard deviation (n = 5) (p < 0.05) expression from BMSC (Fig. 4c) , reduced survival of primary AML cells in vitro, and compromised leukemic colony-forming ability in methylcellulose media assays (Fig. 4d, e) . Moreover, KD of MIF in AML induced apoptosis (Fig. 4f) .
Leukemic cell HIF1α functions to promote tumor proliferation in vivo
In order to track AML disease progression in vivo, we transduced OCI-AML3 cells with a luciferase construct that Fig. 3 HIF1α but not HIF2α regulates MIF mRNA and protein expression in AML blasts. a OCI-AML3 and primary AML blasts were cultured under hypoxic conditions for 4 h to detect HIF1α and 12 h to detect HIF2α, protein was extracted and Western blotting performed. b OCI-AML3, U937 and primary AML blasts were cultured under hypoxic conditions for 6 h to detect HIF2α, protein was extracted and Western blotting performed. Lentiviral knockdown (KD) of HIF1α or HIF2α in AML blasts was determined by RT-PCR for mRNA expression. Data represented as mean ± standard deviation (n = 5) (c) and Western blotting for protein expression (d) under hypoxic conditions. e MIF protein expression in culture media from HIF1α or HIF2α-KD blasts compared to control-KD (ShE) cells was determined by ELISA. Data represented as mean ± standard deviation (n = 5). f Control-KD (ShE) and HIF1α or HIF2α KD AML blasts were cultured for 10 days post infection in hypoxia; cell survival was measured using CellTiter-Glo Luminescent Cell Viability Assay. Data represented as mean ± standard deviation (n = 5). g Control-KD (ShE) and HIF1α or HIF2α KD primary AML blasts were cultured for 24 h in hypoxia while treated with MIF (100 ng/ml); cell survival was measured using CellTiter-Glo Luminescent Cell Viability Assay. Data represented as mean ± standard deviation (n = 5) (p < 0.05) is detectible by bioluminescence (BLI) in live animals. OCI-AML3-luc cells were then infected with control lentivirus (ShE-KD) or HIF1α-KD or MIF-KD lentivirus. NSG mice (6-8 weeks) were injected with 0.5 × 10 6 modified OCI-AML3-luc cells from ShE-KD or HIF1α-KD or MIF-KD cultures. Animals were imaged at day 21 and 28 post injection. At both time points, mice transplanted with HIF1α-KD and MIF-KD cells had lower BLI detection compared to control ShE-KD transplant animals (Fig. 5a,  b) . Figure 5c shows that NSG mice engrafted with HIF1α-KD or MIF-KD OCI-AML3-luc cells had significantly increased survival compared to control animals (n = 4). To show that AML engrafted the bone marrow of NSG mice in ShE-KD or HIF1α-KD or MIF-KD, we analyzed human CD45 expression; the results show that in all treatment groups AML was present in the bone marrow after the end point of the experiment was reached (Fig. 5d ).
Discussion
We have previously shown that MIF is an important mediator of AML survival. Here we report that hypoxia acting through HIF1α is responsible for the up-regulation of MIF and subsequent proliferation and survival of AML in the tumor microenvironment. We find that AML in the BM has increased levels of MIF compared to AML in the PB or spleen. We show that under hypoxic conditions MIF is . c ShE-KD and MIF-KD Primary AML blasts were cultured with BMSC for 4 h, then IL-8 mRNA expression in BMSC was confirmed by RT-PCR. d ShE-KD and MIF-KD cells were cultured in basal media for 10 days post infection in hypoxia; cell survival was measured using CellTiter-Glo Luminescent Cell Viability Assay. e Colony-forming assays of ShE-KD and MIF-KD cells were performed in methylcellulose media. f Apoptosis assays of ShE-KD and MIF-KD cells were performed using annexin V and propidium iodide. Data represented as mean ± standard deviation (n = 5) (p < 0.05) upregulated at both the transcriptional and protein levels, and functionally the hypoxia/HIF1α/MIF axis promotes tumor survival and proliferation of AML within the BM microenvironment in vivo.
AML arises from malignant transformation and proliferation of hematopoietic progenitor cells in the BM. Under physiologic non-malignant conditions the BM has been identified as a hypoxic environment; Fiegl et al. have established that the AML BM is also hypoxic [24] . In addition, tumor-specific transcriptional programs in AML patient samples include an up-regulation of the hypoxic response gene signature [25] . Moreover, hypoxia has as broader malignant phenotype in the proliferation of solid tumor cells in studies of breast, prostate and ovarian cancers [26] [27] [28] . Here, we describe a significant mechanism by which hypoxia is pro-tumoral in the AML microenvironment.
We report that a functional consequence of the hypoxic tumor microenvironment in AML is the up-regulation of the chemokine MIF. Previously, we have shown that AMLderived MIF functions to re-program the tumor microenvironment by inducing BM-MSC-derived IL-8 [29] .
Interestingly, others have shown that hypoxia regulates MIF expression in endothelial cells [30] and vascular smooth muscle cells [15] . Moreover, hypoxia-induced MIF expression is dependent upon a HRE in the 5′-UTR of the MIF gene [31] . In addition, MIF has recently been shown to be upregulated by hypoxia in several tumor cell types in vitro including breast carcinoma cells [31] . Interestingly, a number of studies have shown a complex relationship between HIF1α and MIF exists in chronic lymphocytic leukemia [33] . It has been shown that MIF can regulate and be regulated by HIF1α. Moreover, MIF regulation has been shown to be both dependent and independent of HIF1α [33] . In our work on AML, we demonstrate that silencing HIF1α inhibits transcriptional regulation of MIF under hypoxia.
In our model, KD of HIF1α in primary AML cells significantly reduces survival of AML cells in culture and significantly increases survival of NSG mice engrafted with HIF1α-KD OCI-AML3-luc cells. Previously published results using a murine AML model show that genetic deletion of HIF1α has no effect on mouse AML maintenance and may accelerate disease development [10] . The showing engraftment of OCI-AML3, which was measured using human CD45. In the dot plot, each AML engraftment into NSG mice is shown for control-KD (ShE) and HIF1α-KD same group further shows that loss of HIF1α accelerates murine FLT3-ITD-induced myeloproliferation [34] . However, others have shown that deleting HIF1α in a subset of primary AML leukemic stem cells leads to a decrease in sensitivity of these cells to HIF1α inhibition [7] . Moreover, in their work, Wang and colleagues demonstrated an important role for HIF1α in the in vitro colony-forming activity of their seven clinical AML samples with experiments using treatment with echinomycin (a HIF1α inhibitor) [7] . Echinomycin has also been shown to inhibit growth and induce apoptosis of AML cells lines [35] . Vukovic et al. reported that HIF1α and HIF2α are not required for leukemia stem cell maintenance and AML propagation, but they act synergistically to suppress leukemia development in mice, in their models, knockout of HIF2α or pharmacological inhibition of the HIF pathway in human AML cells has no impact on their survival and proliferation under hypoxic conditions [36] . In our studies, we show that HIF2α was detected in the majority of AML samples and cell lines under normoxic conditions. Moreover, this was not increased under hypoxic condition. We used U937 as a positive control and showed that this cell line did increase HIF2a under hypoxia. These results suggest that HIF2α is regulated in AML without the need for hypoxia as is the case for other tumors [32, 37] . Together, there are a lot of conflicting data regarding the regulatory role of HIF1α in normal HSC and malignant AML cells. In this manuscript we describe a HIF1α-driven mechanism which results in up-regulation of MIF in a tumor-specific manner. Moreover, in vivo KD of HIF1α in AML showed a decreased tumor burden and had an increased survival compared to control AML, thus suggesting that human AML benefits from the hypoxic bone marrow microenvironment.
Previously published studies observed that HIF2α is constitutively expressed in a number of AML subtypes and overexpression studies of HIF2α accelerated myeloid leukemia in mice [13] . Rouault-Pierre and colleagues show that cells from primary AML samples are dependent on the level of HIF2α for their survival and protection from apoptosis induced by ER stress. The degradation kinetics of HIF1α and HIF2α also differ although they are~60% homologous. HIF2α has been shown to be detectable in normoxic condition, while HIF1α has not [38] . Although the similarity in homology contributes to overlapping genes/targets regulated by both HIF1α and HIF2a, each also regulates a distinctive set of genes in their own right and which is supported by our in silico analysis. Moreover, our results also show that HIF2α constitutively expressed under normoxia and hypoxic conditions had little or no effect on its expression. KD of HIF2α in primary AML cells did not reduce MIF expression or secretion from primary AML. Thus suggesting that MIF is not regulated by HIF2α. Our results however, do support studies showing HIF2α expression is heterogeneous in AML subtypes [13] .
Finally, we found that knocking down MIF significantly reduces AML survival and colony-forming ability in vitro, moreover, animals transplanted with AML cells post MIF-KD had significantly improved survival compared to controls; these results in the context of recent clinical observations of the use of novel MIF inhibitors in colorectal cancer and in solid tumors early phase trials are effective and well tolerated [39, 40] , which suggests the plausibility of a MIF inhibitor trial in patients with AML. In conclusion, our study presents a mechanism linking hypoxia to a chemokine factor pro-tumoral signaling pathway in AML microenvironment. In doing so we establish a potential strategy to target AML, a hypoxia-driven malignancy. 
Materials and methods

Methods
Cell cultures
The AML-derived cell lines were obtained from the European Collection of Cell Cultures, where they are authenticated by DNA fingerprinting. All cell lines are tested for mycoplasma contamination. Primary AML blasts were obtained from patient bone marrow or blood following informed consent and under approval from the United Kingdom Health Research Authority (LRECref07/H0310/ 146). For primary AML and BMSC cell isolation, heparinized bone marrow and blood were isolated by density centrifugation using Histopaque which has been previously described [41] . Primary AML and BMSC cells and cell lines were cultured in growth medium comprising Dulbecco's modified Eagle's medium and 10% fetal bovine serum and 1% L-glutamine at 5% CO 2 at 37°C.
Hypoxic assays
For hypoxic cultures, cells were incubated in a hypoxia chamber (Billups-Rothenberg Inc, Del Mar, USA) with 1% O 2 /5% CO 2 /N 2 200 bar. The chamber was incubated at 37°C for indicated times. Control cell cultures, not deprived of oxygen, were incubated under normal conditions. Cobalt chloride (CoCl 2 ) and DFO were added to cell cultures at indicated concentrations and time points.
Clonogeneic methylcellulose assay AML blasts were plated in complete methylcellulose medium supplemented with cytokines (R&D Systems, Abingdon, UK) at a density of 1 × 10 3 . Light microscopy was used to visualize and count colonies at days 10-14.
Flow cytometry
Cells were collected by centrifugation for 3 min at 2000 rpm, then washed and resuspended in phosphatebuffered saline, incubated for 5 min with the FcR blocking reagent and then stained with anti-CD45, anti-CD34 or anti-CD33 or isotype control. Analysis was performed on a CyFlow ® Cube 6 flow cytometer (Sysmex, Milton Keynes, UK).
Cell viability assay
Cell viability was measured using the Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega, Southampton, UK) according to the manufacturer's instructions.
RNA extraction and real-time PCR
ReliaPrep RNA extraction kit from Promega (Southampton, UK) was used to extract total RNA. PCRBIO cDNA synthesis kit (PCR Biosystems, London, UK) was used to generate cDNA from total RNA. Relative quantitative realtime PCR using qPCRBIO SyGreen Mix (PCR Biosystems) was performed as previously described [41] . mRNA expression was normalized against β-actin mRNA expression.
Western immunoblotting and ELISAs
Briefly, whole-cell lysates were extracted and SDS PAGE gel electrophoresis separation performed as previously described [42] . Western blot analysis performed with anti-HIF1α and anti-HIF2α antibody, membranes were reprobed for β-actin as a loading control. MIF chemokine expression in the media we used target-specific MIF ELISA (R&D Systems).
shRNA silencing of MIF, HIF1α and HIF2α
Mission shRNA-targeted lentivirus plasmids (SigmaAldrich) were used to generate lentivirus as previously described [43] . OCI-AML3 cells were infected with pCDHluciferase-T2A-mCherry [44] . OCI-AML3 cells expressing mCherry (OCI-AML3-luc) were sorted on a FACSAria (BD Biosciences). The MIF-KD and the HIF1α-KD in vivo experiments were carried simultaneously, therefore the same control-KD (ShE-KD) mice were used for both MIF-KD and HIF1α-KD mice (Figs. 2g-i, 3e-g ).
OCI-AML3-luc xenograft model
NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ (NSG) mice from The Jackson Laboratory (Bar Harbor, ME, USA) were used for this study. All animal experiments were performed in accordance with UK Home Office approvals and regulations and with approval from the Animal Welfare and Ethical Review Board of the University of East Anglia. 0.5 × 10 6 OCI-AML3-luc cells were intravenously injected into the tail vein of non-irradiated 6-8-week-old NSG mice. When clinical signs of illness became apparent, mice were sacrificed. Bone marrow (BM) and spleen were harvested and analyzed for human CD45 expression. No animals were excluded from experiments and no randomization was used. No blinding was used.
PDX model
Primary AML were cultured in vitro as previously described [45] . A total of 2 × 10 6 viable AML cells were injected into the tail vein of non-irradiated 6-8-week-old female NSG mice. When clinical signs of illness became apparent, mice were sacrificed . BM and spleen were harvested and analyzed for human CD33 and CD45.
Bioinformatic analysis
Publicly available RNA sequencing data were downloaded for a panel of 43 AML patients, which comprised 22 AML samples obtained from PB and 21 AML samples obtained from BM aspirate (Gene Expression Omnibus Accession ID: GSE49642). RPKM data for MIF were extracted and processed further by first replacing zero-valued entries with one followed by logarithmic transformation to the base 2.21. MIF RPKM values for blood and bone marrow samples were compared with a Wilcoxon rank-sum test. Data were extracted for genes that have been shown to be upregulated as a result of HIF1α overexpression, HIF2α overexpression and hypoxia [23] .These data were processed further by first replacing zero-valued entries with one, and followed by logarithmic transformation to the base 2.
Statistical analyses
For Western blotting, data are representative images of three independent experiments. Calculations were made using the software G*Power. The Mann-Whitney U test was used to compare test groups where stated in the legends. Results where p < 0.05 were considered statistically significant and denoted by asterisk. Results represent the mean ± standard deviation of four or more independent experiments. We generated statistics with Graphpad Prism5 software (Graphpad, San Diego, CA, USA).
